A Phase II Clinical Study on Precision Treatment of Rare Tumours in China Guided by Patient-Derived Tumor Organoids (PDO) and Next-Generation Sequencing (NGS)

The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.

开始日期2025-01-01

申办/合作机构

北京大学深圳医院

NCT06440850 / Recruiting临床2期IIT

A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy

This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.

开始日期2024-11-30

申办/合作机构

Hope Medical Center

[+1]

NCT06561360 / Recruiting临床2期IIT

A Randomized, Multi-Center, Phase II Study of Vemurafenib Plus Obinutuzumab Vs. Cladribine Plus Rituximab in Patients with Previously Untreated Hairy Cell Leukemia (HCL)

The researchers are doing this study to compare the safety of vemurafenib in combination with obinutuzumab to the standard of approach of cladribine in combination with rituximab. The researchers will look at which treatment causes fewer or milder side effects. Researchers think vemurafenib and obinutuzumab (non-chemotherapy drugs) may cause fewer side effects compared with the usual approach of chemotherapy drugs. They will also compare the two approaches to see which approach is more effective at eliminating cancer cells.

开始日期2024-09-09

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+1]

100 项与维莫非尼相关的临床结果

登录后查看更多信息

100 项与维莫非尼相关的转化医学

登录后查看更多信息

100 项与维莫非尼相关的专利（医药）

登录后查看更多信息

2,607

项与维莫非尼相关的文献（医药）

2024-12-31·CNS Oncology

Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review

Review

作者: Shahlaie, Kiarash ; Yu, Nina ; Aboud, Orwa ; Raafat, Tarek A ; Raslan, Osama A ; Theeler, Brett J ; Lee, Han Sung ; Fragoso, Ruben

Craniopharyngiomas are tumors that arise from the remnants of Rathke's pouch along the nasopharynx to the diencephalon. Current standard of care includes maximal surgical resection versus adjuvant radiation if a maximal resection is unfeasible. Pharmacological therapy with MAPK targeted agents is an emerging therapeutic option for tumors with BRAF V600E mutations. We report a 45-year-old male with a strictly third ventricle papillary craniopharyngioma with a BRAF V600E mutation. After initial surgery with subtotal resection, the patient demonstrated durable response to targeted BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib. Our report suggests that targeted therapy may reduce the need for radiation and impact surgical interventions in select cases.

2024-12-01·Bioorganic & Medicinal Chemistry

A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors

Review

作者: Bansal, Yogita ; Bansal, Gulshan ; Gupta, Saurabh ; Kashyap, Mayank

Vascular endothelial growth factors (VEGFs) are a class of homodimeric ligands that bind to their receptors (VEGFRs) to carryout physiological and pathological angiogenesis essential for regulating homeostasis of body. Overexpression of VEGF results in metastasis of benign tumor into malignant tumor. An active role of VEGFR-2 in cancer angiogenesis makes it a major target for cancer therapy. FDA approved VEGFR-2 inhibitors like sorafenib, vemurafenib and dabrafenib, and monoclonal antibodies such as bevacizumab and ramucirumab are available in market but possess side effects like hypertension, CVS disorders, liver damage and adverse effects like Iatrogenicity. Several research groups across the globe have designed and reported varied small molecules from different heteronuclei like quinazoline, pyrimidine, coumarin, pyrazole, indoline, benzimidazole, benzoxazole, etc. as VEGFR-2 inhibitors based on the information available on active site of the receptor, and pharmacophoric features of FDA approved drugs. The present review compiles the information available on benzo-fused heteronuclear compounds including benzimidazole, benzoxazole and benzothiazole in recent years, with emphasis on their design, activity, structure-activity relationship (SAR) and docking analysis for understanding binding interactions in the active site of VEGFR-2. In addition to this, a topological similarity analysis of these compounds is performed taking sorafenib as template, and a comprehensive SAR is proposed for researchers to further explore the anticancer potential of these pharmacophore.

2024-12-01·European Journal of Pharmaceutical Sciences

A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells

Article

作者: Király, József ; Szabó, Erzsébet ; Herczegh, Pál ; Tósaki, Ágnes ; Vass, Virág ; Szabó, Zsuzsanna ; Bereczki, Ilona ; Lőrincz, Eszter Boglárka ; Remenyik, Éva ; Tánczos, Bence ; Tósaki, Árpád

Despite the targeted- and immunotherapies used in the past decade, survival rate among patients with metastatic melanoma remains low, therefore, melanoma is responsible for the majority of skin cancer-related deaths. The ongoing investigation of natural antitumor agents, the nonpsychoactive cannabinoid, cannabigerol (CBG) found in Cannabis sativa is emerging as a promising candidate. CBG offers a potential therapeutic role in the treatment of melanoma demonstrating cell growth inhibition in some tumors. Its low water solubility and bioavailability hinder the potential effectiveness. To address these challenges, a modified CBG, namely LE-127/2 was synthesized by Mannich-type reaction. The aim was to investigate the effect of this novel compound on cell proliferation as well as the mechanism of cell death with a particular focus on autophagy and apoptosis. Human cutan melanoma cell lines, WM35, A2058 and WM3000 were utilized for the present study. Cell proliferation of the cells after the treatment with LE-127/2, parent CBG or vemurafenib was assessed by Cell Titer Blue Assay. Cells were treated with a 1.25-80 µM of the above-mentioned compounds, and it was found that at 20 μM of all drugs showed a comparable effective inhibition of cell proliferation, however, vemurafenib and CBG proved to be more effective than LE-127/2. In addition, clonogenic cell survival assays were performed to examine the inhibitory effect of LE-127/2 on the colony formation ability of melanoma cell lines. Cells treated with 20 µM of LE-127/2 for 14 days showed about a 50% suppression of clonogenic cell survival. LE-127/2 exerted the most intensive inhibition on A2058 cell colonies. Furthermore, notably, LDH cytotoxicity assay performed on HaCaT cell line, proved LE-127/2 to be cytotoxic only at higher concentration, such as 80 μM, while the parent CBG was cytotoxic at concentration as low as 5 μM, suggesting that the new CBG derivative as a drug candidate may be applied in human pharmacotherapy without causing a substantial damage in intact epidermal cells. Analysis of protein expression revealed the impact of LE-127/2 on the expression of basic proteins (LC-3, Beclin-1 and p62) involved in the process of autophagy in the three different melanoma cell lines studied. Elevated expression of these proteins was detected as a result of LE-127/2 (20 µM) treatment. LE-127/2 also induced the expression of some proteins involved in apoptosis, and it is particularly noteworthy the increased level of cleaved PARP. Based on the results obtained, it can be concluded that LE-127/2 induced autophagy could lead to the inhibition of cell proliferation and death in melanoma cells.

项与维莫非尼相关的新闻（医药）

2024-11-08

·CPHI制药在线

MEK抑制剂研究进展

关注并星标CPHI制药在线在癌症治疗领域，针对细胞内信号通路的靶向治疗一直是研究的热点。MEK（丝裂原活化蛋白激酶激酶）作为MAPK（丝裂原活化蛋白激酶）信号通路中的关键激酶，其抑制剂的研究取得了显著的进展，为肿瘤治疗带来了新的希望。或许很多人会说：“我从来没有听说过MEK这个靶点呀？”但是，肯定有很多人听说过一条颇有名气的信号通路——MAPK。在包括NSCLC、黑色素瘤和结肠癌在内的多种肿瘤中，这一通路均被发现存在激活。一、什么是MEK？ MEK处于 RAS-RAF-MEK-ERK通路的中间环节，该通路在细胞增殖、分化和存活中发挥着重要作用。当这一通路发生异常激活时，会导致细胞的异常生长和癌症的发生发展。因此，抑制MEK 的活性成为了一种有潜力的癌症治疗策略。 MEK是一种双重特异性蛋白激酶（线粒体活性蛋白激酶）的编码基因，除此之外，它还有一个非常洋气的名字叫做MAP2K。所谓激酶，我们可以理解为使其它分子“激动”的酶。当MEK把自身ATP的高能磷酸“献给”另一个蛋白（也称作底物分子磷酸化）的时候，这个蛋白的某些氨基酸便能够“激动地”收获这一磷酸，该蛋白也因此获得了更高的能量。我们可以把MAPK信号通路想象成从细胞表面通往细胞核的一条高速公路，那么该通路的每一个分子都是一个重要的传递使者（细胞内信使），它们通过磷酸化方式来传递信息。我们所关注的MEK蛋白激酶位于MAPK信号通路的中游，在上游，它可以被RAS和RAF相继激活；而在下游，MEK能够作用于该通路最后的一个信号分子——ERK。当磷酸化的ERK进入细胞核内时，便有可能改变细胞从生长发育到增殖分化的多种生理过程，给身体健康带来很大的麻烦。 MAPK信号通路示意图图片来源：http://dx.doi.org/10.1016/j.ctrv.2016.12.001 这些信使分子看似有点陌生，但在比如非小细胞肺癌NCCN指南所推荐的八大检测靶点中，EGFR、KRAS和BRAF三个靶点的突变都与MAPK信号通路异常有关。并且，这三个基因在NSCLC中一点也不罕见，发病率加起来甚至能够达到70%~80%。由于迄今为止，ERK仍然是MEK 蛋白激酶唯一已知的作用分子。这种紧密的选择性使得MEK在把控MAPK通路的信号传递上发挥了重要的战略作用，许多针对该信号通路的药物也将研发目标放在抑制这一关键的蛋白上。目前已知的蛋白激酶的根据其作用位点主要分为丝氨酸/苏氨酸蛋白激酶、酪氨酸蛋白激酶和组氨酸蛋白激酶。而MEK之所以属于双重性激酶，正是因为其作用位点不是一个，而是两个！它既可以选择性地磷酸化底物分子的丝氨酸/苏氨酸，同时也能够磷酸化酪氨酸。除了能够激活其它蛋白外，MEK的独特意义也体现在其自身能够被其上游的蛋白激活。了解了蛋白的功能后，再来看其结构或许会容易许多。MEK有三个关键结构域（图1），其中部的核心结构域包含有ATP和催化位点，其它的两个结构域则分别起着连接的功能，负责与其它蛋白相互作用。实际上，MEK属于一个庞大的蛋白家族，该家族成员能够由7个不同的基因所编码，其中的MEK1和MEK2具有重要意义。二、MEK抑制剂有哪些靶向药获批上市了？近年来，多种 MEK抑制剂被研发出来，并在临床试验中展现出了一定的疗效。这些抑制剂通过与MEK 蛋白结合，阻断其磷酸化活性，从而抑制下游信号的传递。截止2024年5月，全球已上市5款MEK1/2抑制剂： 1.阿斯利康：司美替尼（Selumetinib、科赛优），国内已上市，可医保报销；作用靶点：MEK 规格剂量：10毫克*60粒；25毫克*60粒中国上市：2023年5月国内首次获批上市医保报销适应症/报销条件：医保乙类，用于 3 岁及 3 岁以上伴有症状、无法手术的丛状神经纤维瘤（PN）的 1 型神经纤维瘤病（NF1）儿科患者的治疗；医保报销前价格：10毫克*60粒（11187元/盒）；25毫克*60粒（22560元/盒）用法用量：服用方法是空腹（餐前2小时或餐后1小时），用水送服，不可掰开胶囊或咀嚼，剂量为25mg/m2每天两次，直至疾病进展或出现不可接受的毒性。临床效果：司美替尼的获批是基于开放标签、多中心的单臂研究SPRINT试验（NCT01362803），参与该试验的NF1儿童患者携带无法通过手术治疗的丛状神经纤维瘤（PN）。试验结果显示，司美替尼的治疗使患者的总缓解率（ORR）达到66%，所有患者均达到部分缓解，且有82%的患者持续缓解至少12个月。 2.诺华：曲美替尼(Trametinib、迈吉宁)，国内已上市，可医保报销；作用靶点：BRAF V600E 中国上市：2022年3月，首次国内获批上市 2024年最新价格：9976.5元/盒医保报销：医保乙类，可医保报销用法用量：口服，2mg，每日一次，需联合甲磺酸达拉非尼治疗，直至出现疾病进展或不可耐受的毒性反应。 3.罗氏/Exelixis：考比替尼（Cobimetinib）；药品英文名：Cobimetinib 美国获批上市：2015年11月首次获批上市美国版价格：8103美金/盒中国上市：国内未获批上市医保报销：未在国内上市，不能医保报销适应症：1、考比替尼是一种激酶抑制剂，适用为患者有不能切除或转移黑色素瘤有一个BRAF V600E或V600K突变，与威罗菲尼联用的治疗。2、使用限制：考比替尼不适用为有野生型BRAF黑色素瘤患者的治疗。用法用量：推荐剂量：每28天一个疗程，前21天每天一次口服60 mg，28天为一周期，直至疾病进展或不可接受毒性。临床效果：黑色素瘤：维莫非尼联合考比替尼治疗BRAF突变的晚期黑色素瘤患者，无进展生存期PFS为12.3个月，比威罗非尼单药组（PFS7.2月）延长5个月。结直肠癌：PDL1单抗阿特朱单抗联合考比替尼治疗KRAS突变的结直肠癌患者，有效率ORR是20%。试验中也包含微卫星稳定MSS的结直肠癌患者，此类患者单用免疫治疗的疗效一般，但联合考比替尼后可以改善免疫微环境来提高MSS患者的整体免疫疗效。 4.辉瑞：比美替尼（Binimetinib）；美国上市：2018年6月份首次获批上市中国获批上市：国内未获批上市适应症：比美替尼是一种激酶抑制剂，与康奈非尼（encorafenib）联合用于治疗患有BRAFV600E或V600K突变的不可切除或转移性黑色素瘤患者。 5.科州制药：妥拉美替尼（tunlametinib，商品名：科露平），国内已上市。作用靶点：MEK1/2 2024年最新价格：9390元/瓶规格剂量：3mg*56粒/瓶中国上市时间：2024年3月医保报销适应症：截止2024年9月份，尚未纳入医保报销目录，不能医保报销首次获批适应症：NRAS突变的晚期黑色素瘤，适用含抗 PD-1/PD-L1 治疗失败的 NRAS 突变的晚期黑色素瘤患者。用法用量：科露平可用于含抗PD-1/PD-L1 治疗失败的NRAS 突变的晚期黑色素瘤患者，推荐剂量是每次12mg，每日两次口服（约每12小时服用一次），空腹或随餐均可。临床效果：在 2023 ASCO 年会上公布了妥拉美替尼针对晚期 NRAS 突变黑色素瘤患者的?Ⅱ 期关键注册临床研究结果。该研究共纳入 100 例晚期 NRAS 突变黑色素瘤患者，采用妥拉美替尼 12 mg 每日两次连续给药口服治疗。95 例受试者纳入有效性分析，主要研究终点——经独立影像评估委员会确认的?ORR 为 34.7%，中位 PFS 为 4.2 个月，DCR 为 72.6%，其中既往接受过免疫治疗患者 ORR 高达 39.1%。所有患者均纳入安全性分析，安全性数据显示，妥拉美替尼安全耐受性性良好，未发现非预期不良事件，本研究未发生与研究药物相关导致死亡的 AE。三、部分在研MEK抑制剂目前，多个MEK抑制剂已经进入不同的研发阶段，涉及的企业包括复星医药、罗氏、NFlection Therapeutics、武田、恒瑞医药、辉瑞/Springworks Therapeutics、正大天晴、基石药业、璧辰医药以及Pasithea Therapeutics等。 1、FCN-159，2024年5月20日，复星医药的「FCN-159片」被CDE拟纳入优先审评，用于治疗2岁及2岁以上儿童1型神经纤维瘤病（NF1）相关的丛状神经纤维瘤（PN）；2024年4月，该药被CDE纳入优先审评，用于治疗成人树突状细胞和组织细胞肿瘤。 2、Avutometinib，由罗氏研发，处于II期临床阶段，针对卵巢癌、胰腺癌、宫颈癌等多种癌症。美国食品和药物管理局（FDA）批准了突破性治疗指定，将Avutometinib 和Defactinib（一种选择性 FAK 抑制剂）的研究组合用于治疗所有复发性低级别浆液性癌症（LGSOC）患者，无论其在一种或多种先前的治疗方案（包括基于铂的化疗）后的 KRAS 状态如何。Avutometinib 单独或与 defactinib 联合使用也被美国食品药品监督管理局授予孤儿药指定，用于治疗 LGSOC。 3、NFX-179，由NFlection Therapeutics研发，同样处于II期临床阶段，用于治疗1型神经纤维瘤病等。 4、TAK-733，由武田研发，针对家族性腺瘤性息肉和胃癌。 5、SHR-7390，由恒瑞医药研发，用于治疗乳腺癌等实体瘤。 6、Mirdametinib，由辉瑞和Springworks Therapeutics共同研发，针对丛状神经纤维瘤和实体瘤。 7、TQ-B3234，由正大天晴研发，处于I期临床阶段，用于治疗1型神经纤维瘤病。 8、CS-3006，由基石药业研发，针对实体瘤。 9、ABM-168，由璧辰医药研发，用于治疗晚期实体瘤。 10、CIP-137401，由Pasithea Therapeutics研发，目前处于临床前阶段，用于治疗1型神经纤维瘤病和努南综合征。总之，MEK 抑制剂在癌症治疗中的研究进展令人鼓舞，但仍有许多问题需要进一步解决。随着研究的不断深入，相信MEK 抑制剂将在癌症治疗中发挥更重要的作用，为患者带来更多的生存获益和生活质量的提高。未来，我们期待更多关于 MEK 抑制剂的创新性研究成果，为癌症治疗开辟更广阔的前景，实现更精准、更有效的肿瘤治疗，为众多癌症患者带来新的曙光。参考文献：【1】Yaeger R, Corcoran R B. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019 Mar;9(3):329-341. 【2】Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clin Cancer Res. 2015 Apr 15;21(8):1935-43. 【智药研习社线上研习会报名】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床研究

2024-10-25

·精准药物

胶质瘤NCCN指南更新及分子标志物相关靶免药物总结

导语在过去20多年，胶质瘤治疗领域的突破性进展寥寥无几。然而，今年似乎按了加速器，先后有3款药物：Tovorafenib、伯瑞替尼、Vorasidenib，获得突破性成功，成为对应靶点在胶质瘤中的首款获批药物。这些新药的获批共同开启了脑胶质瘤精准诊疗的新篇章。Vorasidenib也于9月30日纳入NCCN指南。本期就指南更新内容进行介绍，同时对胶质瘤分子标志物相关的靶免药物进行汇总分享，以便读者全面了解。一、NCCN指南更新 2024年8月6日，FDA批准Vorasidenib用于治疗手术后（包括活检、次全切或全切）携带IDH1/2突变的2级星形细胞瘤或少突胶质细胞瘤的12岁及以上患者。2024年9月30日，中枢神经系统癌症NCCN指南从2024V2版更新升级为2024V3版，纳入Vorasidenib并扩大其适应症范围，具体更新内容如下：在GLIO-A 2/9和GLIO-A 4/9页面中的以下4个临床场景中添加靶向IDH1或IDH2突变的Vorasidenib作为治疗选择： 01 作为手术/活检后的辅助治疗方案，用于RT和化疗不是首选、WHO2级、KPS≥60的患者： ►少突胶质细胞瘤（1类），首选 ►IDH突变的星形细胞瘤（1类），首选 ►注脚修改：Vorasidenib是IDH1和IDH2突变的双重抑制剂。在一项Vorasidenib对比安慰剂的3期研究中（Mellinghoff IK, et al.N Engl J Med 2023;389:589-601），在病灶残留或复发的2级IDH突变胶质瘤患者（手术后且未接受治疗）中，与安慰剂相比，Vorasidenib改善了中位PFS（27.7个月vs 11.1个月）。虽然Vorasidenib的FDA批准程序仍在进行中，但符合条件的新诊断的WHO2级疾病患者可以通过扩大准入计划（NCT05592743）获得Vorasidenib。同样适用于GLIO-2A、GLIO-4A页面的脚注k。 02 作为辅助治疗方案，用于KPS <60、WHO2级的患者 ►少突胶质细胞瘤（2A类），在某些情况下适用 ►IDH突变星形细胞瘤（2A类），在某些情况下适用 03 作为RT+化疗后复发或进展性疾病的治疗方案，用于WHO2级、KPS≥60的患者 ►少突胶质细胞瘤（2A类），首选 ►IDH突变星形细胞瘤（2A类），首选 04 作为复发或进展性疾病的治疗方案，用于KPS ≥60的患者 ►少突胶质细胞瘤，WHO3级（2B类），首选 ►IDH突变型星形细胞瘤，WHO3级或4级（2B类），首选 ▼IDH突变、1p19q共缺失的少突胶质细胞瘤：系统治疗方案选择 ▼IDH突变的星形细胞瘤：系统治疗方案选择二、胶质瘤分子标志物相关的靶免药物汇总 2.1 获批或指南推荐检测的分子标志物及其药物 1 靶向药物分子标志物：IDH1/2 异柠檬酸脱氢酶（IDH）是三羧酸循环中的一种关键性限速酶，包括IDH1、IDH2和IDH3这3种异构酶，其功能是催化异柠檬酸生成α-酮戊二酸（α-KG）。IDH的特定突变会导致α-KG的代谢异常，D-2-羟戊二酸（D-2-HG）高浓度积累，引起基因的表观修饰异常和氧化还原失衡。超过90%的IDH基因突变为IDH1 R132 突变（常见R132H突变），其余为IDH2 R172突变。 ▼胶质瘤中IDH突变频率、突变类型及其占比 Vorasidenib Vorasidenib（AG-881）是首个获批应用于胶质瘤中的IDH抑制剂。其获批基于INDIGO临床试验（NCT04164901），该试验是一项3期、多中心、随机、双盲、安慰剂对照研究，比较了Vorasidenib与安慰剂在仅接受过手术治疗的IDH1或IDH2突变的2级胶质瘤（少突胶质瘤、星形细胞瘤）残余或复发性患者中的疗效。试验数据显示，Vorasidenib的客观缓解率（ORR）为18%，包括1例部分缓解（PR）和3例轻微缓解（MR）。使用该药物观察到的无强化低级别胶质瘤患者的中位无瘤生存期为36.8个月（95%CI：11.2-40.8个月），强化胶质瘤患者的中位无瘤生存期为3.6个月（95%CI：1.8-6.5个月）。此外，在多名患者中观察到持续的肿瘤缩小。研究结论指出：在2级IDH突变胶质瘤患者中，Vorasidenib显著提高了无进展生存期，并延迟了下一次干预的时间。艾伏尼布艾伏尼布是首个获指南推荐应用于胶质瘤的IDH1抑制剂。该推荐基于以下研究结果：在66例晚期胶质瘤患者中，艾伏尼布耐受性良好，无剂量限制性毒性报道。未达到最大耐受剂量；扩大队列选择500毫克，每天一次。≥ 3 级不良事件发生率为19.7%；3% （n= 2）被认为与治疗有关。非增强型胶质瘤患者（n = 35），客观缓解率为2.9%，部分缓解1例。35例非增强型胶质瘤患者中有30例（85.7%）病情稳定，而31例增强型胶质瘤患者中有14例（45.2%）病情稳定。非增强型和增强型胶质瘤组的中位无进展生存期分别为13.6个月（95% Cl：9.2-33.2个月）和1.4个月（95% Cl：1.0-1.9个月）。在探索性分析中，艾伏尼布降低了非增强性肿瘤的体积和生长速度。结论：在mIDH1晚期胶质瘤患者中，艾伏尼布 500 mg /天1次具有良好的安全性、延长疾病控制时间和减少非增强性肿瘤的生长。目前，还有多款在研的IDH抑制剂，如Olutasidenib、DS-1001（AB-218）的初步研究已表明其在胶质瘤中具有较好的临床应用前景。 2 靶向药物分子标志物：BRAF突变/融合、NF1突变 BRAF基因变异会导致下游MEK/ERK信号通路持续激活，促进肿瘤的生长增殖和侵袭转移。在不同的脑胶质瘤中，BRAF变异的形式不同，主要包括BRAF融合和BRAF V600E。在毛细胞星形细胞瘤（PA，WHO 1级）中高发KIAA1549-BRAF融合（约60%-70%），被认为是PA的诊断标志物。在各个级别的胶质瘤中均检测到BRAF V600E突变，在多形性黄色星形细胞瘤（PXA，WHO 2/3级）中约为70%，在上皮样胶质母细胞瘤中约为50%，在胚胎发育不良性神经上皮瘤（DNET）中约为30%，在节细胞胶质瘤（WHO 1级）中约50%，在PA中约为10%。BRAF基因变异是儿童低级别胶质瘤（LGG）中最常见的致癌驱动因素。神经纤维瘤病1型（NF1）是最常见的常染色体显性肿瘤易感性综合征，由NF1基因胚系突变导致。高达30%的NF1患者会在20岁前患脑肿瘤，其中大部分是低级别胶质瘤，最常见于视觉通路，最常见的病理学亚型是PA。 ▼各类型胶质瘤中 BRAF基因变异频率 ▼常见BRAF融合的断点频率针对BRAF基因变异，NCCN指南推荐用于胶质瘤的靶向药物有：达拉非尼+曲美替尼、维莫非尼±考比替尼、司美替尼，已获药监局批准的药物有Tovorafenib、达拉非尼+曲美替尼。针对NF1基因突变，NCCN指南推荐药物有司美替尼。 Tovorafenib 2024年4月23日，FDA加速批准Tovorafenib（RAF抑制剂）用于BRAF基因融合/重排或BRAF V600突变的6个月及以上复发或难治性儿童低级别胶质瘤患者。这是首个获批用于BRAF融合/重排脑胶质瘤适应症的RAF抑制剂，其获批是基于一项多中心、开放标签、单臂临床试验FIREFLY-1（NCT04775485，II期）的研究结果。FIREFLY-1旨在评估Tovorafenib作为每周一次的单药疗法治疗6个月至25岁患有复发或进展性pLGG患者的疗效与安全性，研究共纳入137名患者（第1组：77名患者携带已知的BRAF激活突变，第2组：60名患者携带已知的RAF变异）。研究结果显示，在第1组RAPNO-LGG标准可评估的76例患者中，最佳ORR为51%，其中包括28例PR（37%）和11例MR（14%），中位持续响应时间（DoR）为13.8个月（95%CI：11.3-NE[不可估计]）。目前正在开展全球III期试验LOGGIC/FIREFLY-2（NCT05566795），旨在评估新诊断的LGG患者每周一次的Tovorafenib单药疗法，入组患者均具有已知的激活RAF改变。司美替尼 NCCN指南推荐用于BRAF变异包括BRAF V600E突变或BRAF融合和NF1突变的复发或进展性局限性胶质瘤成人患者。该推荐基于一项多中心 II 期试验（NCT01089101）的第1组和第3组研究结果：司美替尼对复发性、难治性或进展性伴有常见BRAF变异的PA和NF1相关pLGG具有活性。第1组包括患有WHO 1级毛细胞星形细胞瘤（PA）的儿童，25例符合条件且可评估的肿瘤中有18例（72%）具有 KIAA1549-BRAF融合，有7例（28%）具有BRAF V600E 突变。9例（36%）患者达到PR，9例（36%）疾病稳定（SD）和7例（28%）疾病进展（PD）。2年PFS为70%（95%CI：47%−85%）。在具有 KIAA1549-BRAF 融合的肿瘤中7例（38.9%）PR，而在BRAF V600E肿瘤中2例（28.6%）PR 。第3组包括25例患有任何NF1相关pLGG（WHO 1级和2级）的儿童接受治疗。10例（40%）患者达到 PR，15例（60%） SD和1例（4%）PD。2年PFS为96%（95% CI：74%-99.4%）。 3 靶向分子标志物：MET融合脑胶质瘤中MET异常形式主要有MET融合、MET ex14跳突、MET扩增及MET蛋白过表达；约12%脑胶质瘤被发现存在MET融合，其中PTPRZ1-MET（简称ZM）融合通常与MET ex14跳突同时出现在既往有低级别病史的胶质母细胞瘤中，发生率约为14%，并与更差的预后相关。 ▼MET融合断点（A）及其在5个癌种中的情况（B）和伴侣基因染色体分布（C）注：BC：脑癌，LC：肺癌，IC：小肠癌，GC：胃癌，BDC：胆管癌伯瑞替尼伯瑞替尼（Vebreltinib，PLB-1001）是一种高选择性MET抑制剂，于2024年4月23日获得NMPA批准用于既往治疗失败的具有PTPRZ1-MET融合基因的IDH突变型星形细胞瘤（WHO 4级）或有低级别病史的胶质母细胞瘤成人患者。这使其成为我国首个获批治疗脑胶质瘤MET异常患者的靶向药。获批主要是基于一项随机、对照、开放、多中心的II/III期临床研究（FUGEN，NCT06105619），该研究旨在对比伯瑞替尼与TMZ剂量密度方案或依托泊苷+顺铂方案的安全性和有效性。截至2023年12月，该研究共纳入了84例患者。结果显示，相较于TMZ剂量密度方案或顺铂联合依托泊苷方案，伯瑞替尼单药方案mOS为6.31个月，对照组为3.38个月，降低48%的死亡风险，可显著改善ZM融合脑胶质瘤患者生存。整体安全耐受，常见不良反应多为1-2级，可通过临床管理恢复。 4 靶向药物分子标志物：NTRK融合编码TRK融合蛋白（TRKA、TRKB、TRKC）的基因包括NTRK1、NTRK2或NTRK3的基因，这些基因融合蛋白增加了激酶功能，并与许多实体瘤发生有关。大约0.55-2%的胶质瘤/神经上皮肿瘤含有NTRK融合，但在儿童高级别胶质瘤（HGG）中NTRK融合发生率可能高达5.3%，弥漫性内生性脑桥胶质瘤（DIPG）达4%，3岁以下非脑干HGG达40%。 ▼中枢神经系统肿瘤中NTRK融合的发生率及高频的融合基因类型小分子TRK抑制剂拉罗替尼（Larorectinib，FDA/NMPA）、恩曲替尼（Entrectinib，FDA/NMPA）、瑞普替尼（Repotrectinib，FDA）已在成人和儿童各种癌症的多项试验中显示出抗肿瘤活性，并已获得国内外药监局批准用于NTRK融合的实体瘤患者。目前，针对NTRK融合的成人复发或进展性胶质母细胞瘤以及儿童HGG患者，NCCN指南推荐首选拉罗替尼和恩曲替尼；针对成人患者，2024.V2版NCCN指南新增推荐了瑞普替尼。瑞普替尼瑞普替尼获批基于多中心、单臂、开放标签的I/II期临床试验TRIDENT-1（NCT03093116），该研究纳入了3例TKI经治的胶质母细胞瘤患者，ORR为33.3%，DoR为23.5个月。文献研究报道一名2岁的女性婴儿半球型脑胶质瘤，伴有ZBTB43-NTRK2融合和CDKN2A/2B半合子缺失，在左额颞肿瘤首次手术切除后，接受了诱导化疗，自体外周血干细胞移植（aPBSCT）联合卡铂和塞替派，以及质子治疗（55.8 Gy）。第二次手术切除残留肿瘤后，参加了口服瑞普替尼的临床试验，在3年随访期间未发生疾病复发。 ▼瑞普替尼在TKI经治的NTRK融合胶质母细胞瘤患者中的疗效 ▼NTRK融合的婴儿半球型脑胶质瘤的治疗过程 5 免疫药物分子标志物：超突变遗传性癌症易感性综合征CMMRD（结构性错配修复缺陷综合征，由MMR基因[MLH1、PMS2、MSH2、MSH6]的双等位基因突变导致）经常导致儿童弥漫性高级别胶质瘤的发展，其特点是比偶发脑肿瘤或其他实体肿瘤具有更高的突变负荷。由此产生的超突变肿瘤可能对免疫检查点抑制敏感。针对超突变的复发或进展性的儿童中枢神经系统肿瘤患者，NCCN指南推荐首选纳武利尤单抗、帕博利珠单抗。然而，其有效性的证据目前仅限于病例报告和单一机构的经验。 ▼CMMRD和林奇综合征的遗传模式图（林奇综合征为MMR基因杂合突变，CMMD为MMR基因双等位基因突变）一项研究报告了两个患有复发性多灶性GBM的bMMRD（biallelic MMR deficiency syndrome，同CMMRD）的姐弟，存在POLE突变和高肿瘤突变负荷（预测具有较高的新生抗原），接受了抗程序性死亡-1（PD-1）抑制剂纳武利尤单抗的治疗，在几个月的治疗后，这两个孩子的临床和放射学反应都很明显。另一项案例研究报道，一例5岁女孩存在纯合MSH6 c.1883G>A 突变而患有GBM和CMMRD，接受免疫检查点抑制剂（ICI）纳武利尤单抗治疗，肿瘤缩小了60%，临床症状得到改善，响应持续10个月。研究表明，将CMMRD的基因组和/或分子检测纳入常规儿科肿瘤学临床护理可以确定可能从ICI中受益的患者亚群。一项在丹娜-法伯/波士顿儿童医院对11例复发性或难治性中枢神经系统肿瘤儿童患者进行的回顾性研究显示，免疫检查点抑制剂在儿童患者中具有相当好的耐受性，值得进一步的临床试验研究。 2.2 临床试验/案例报道的其他分子标志物及药物 1 靶向药物分子标志物：ALK融合婴儿半球胶质瘤携带 ALK、ROS1、NTRK1/2/3 或MET受体酪氨酸激酶重排，与其他儿科高级别胶质瘤相比，更适合治疗，生存结果更好。一名3岁的婴儿半球胶质瘤患者肿瘤细胞显示ALK 具有弥漫性免疫反应，RNA 测序显示SPECC1L-ALK融合，于是采用ALK抑制剂洛拉替尼治疗，至8个月，仅残余较小的肿瘤，实行探查性手术后未发现肿瘤，停止治疗6 个月后疾病进展，恢复洛拉替尼治疗，治疗一个月实现几乎完全缓解。另一项案例研究报道，一名3岁婴儿型半球胶质瘤，DNA测序检出QKI-ALK融合，经常规放化疗治疗进展后，采用阿来替尼治疗2个月左右，治疗期间发生肺部转移，更换为洛拉替尼治疗，实现脑部和肺部病灶的完全缓解。 2 靶向药物分子标志物：FGFR变异约有8%的胶质瘤患者会发生FGFR基因组改变，尤其是FGFR1和FGFR3，并且在约3%-5%的GBM患者中存在FGFR3-TACC3（F3T3）融合突变。研究表明F3T3融合是染色体4p16上70kb区域串联复制的结果，通常伴有低水平的局灶扩增，存在该基因融合的肿瘤细胞大量表达嵌合蛋白。FGFR1-TACC1（F1T1）融合在特定的低级别胶质瘤(如室外神经细胞瘤)中可达60%。文献报道1例胶质母细胞瘤患者，携带FGFR3扩增和FGFR3-TACC3融合，经安罗替尼和替莫唑胺治疗2个月后实现部分缓解。原发性脊髓胶质母细胞瘤（PSC GBM）检出FGFR3 p.S249C，接受10个周期的安罗替尼联合伊立替康化疗，随访约10个月期间，患者症状明显减轻，疗效得以维持。有文章报道，两例携带有FGFR3-TACC3融合突变的GBM患者，在接受安罗替尼治疗后疾病得到持续缓解。一项在复发性胶质瘤患者（携带FGFR改变）中进行的多中心II期临床研究（NCT01975701）数据显示，26名接受FGFR抑制剂Infigratinib治疗的患者的6个月PFS率为16.0%，中位PFS为1.7个月，客观缓解率为3.8%。但是4名携带FGFR1（K656E，n = 2) 或FGFR3（ K650E; n = 1）点突变或FGFR3-TACC3融合突变的肿瘤患者疾病控制持续时间超过1年。另外一项临床研究（NCT04083976）报道了FGFR抑制剂厄达替尼在具有FGFR改变的14种实体瘤体治疗中的有效性，其中30名高级别胶质瘤患者的ORR为20%。一项佩米替尼的II期临床研究纳入9例为F3T3融合的胶质瘤（共纳入13例FGFR变异），1例完全缓解，1例部分缓解，2例疾病稳定。目前一项旨在评估佩米替尼在先前治疗过的胶质母细胞瘤或其他原发性中枢神经系统肿瘤患者（携带FGFR1-3改变，包括融合/重排，激活突变或框内缺失）中的疗效和安全性的研究（NCT05267106，II期）正在进行招募中。一项关于Zoligratinib（Debio-1347）的单中心研究纳入5例FGFR变异的儿童胶质瘤患者，1例F3T3融合，1例F1T1融合，在融合的患者中1例PR，1例SD。参考资料【1】 Shen D , Zhang J , Yuan K ,et al.Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis[J].Molecular Genetics & Genomic Medicine, 2021.DOI:10.1002/mgg3.1697. 【2】Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial [published correction appears in Lancet Haematol. 2023 Jan;10(1):e9]. Lancet Haematol. 2023;10(1):e46-e58. doi:10.1016/S2352-3026(22)00292-7 【3】Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589-601. doi:10.1056/NEJMoa2304194 【4】Kilburn LB, Khuong-Quang DA, Hansford JR, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. Published online November 17, 2023. doi:10.1038/s41591-023-02668-y 【5】Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012;18(20):5562-5571. doi:10.1158/1078-0432.CCR-12-1773 【6】Natsume A, Arakawa Y, Narita Y, et al. The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas. Neuro Oncol. 2023;25(2):326-336. doi:10.1093/neuonc/noac155 【7】Mellinghoff IK, Lu M, Wen PY, et al. Vorasidenib and Ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial [published correction appears in Nat Med. 2023 Jul 3;:]. Nat Med. 2023;29(3):615-622. doi:10.1038/s41591-022-02141-2 【8】Di Stefano AL, Fucci A, Frattini V, et al. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res. 2015;21(14):3307-3317. doi:10.1158/1078-0432.CCR-14-2199 【9】Wang Y, Liang D, Chen J, et al. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. Oncologist. 2021;26(3):173-177. doi:10.1002/onco.13530 【10】Liu R, Wei W, Hou H, Cong P, Zhou Y, Yu X. Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation. Onco Targets Ther. 2022;15:771-776. Published 2022 Jul 11. doi:10.2147/OTT.S362185. 【11】Picca A, Sansone G, Santonocito OS, Mazzanti CM, Sanson M, Di Stefano AL. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives. Cancers (Basel). 2023;15(23):5555. Published 2023 Nov 23. doi:10.3390/cancers15235555 【12】Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, et al. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022;28(11):2270-2277. doi:10.1158/1078-0432.CCR-21-2664 【13】Pant S, Schuler M, Iyer G, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24(8):925-935. doi:10.1016/S1470-2045(23)00275-9 【14】Spanggaard, I.; Matrana, M.; Rocha-Lima, C.; Mahipal, A.; Vieito, M.; Hervieu, A.; Ahn, M.-J.; Goyal, L.; Ahnert, J.R.; Veronese, L.;et al. Pemigatinib For Previously Treated Central Nervous System Tumors With Activating FGFR Mutations or Translocations: Results From FIGHT-207 (S17.004). Neurology 2023, 100, 4218. 【15】Farouk Sait S, Gilheeney SW, Bale TA, et al. Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas. JCO Precis Oncol. 2021;5:PO.20.00444. Published 2021 May 20. doi:10.1200/PO.20.00444 【16】Lasorella A, Sanson M, Iavarone A. FGFR-TACC gene fusions in human glioma. Neuro Oncol. 2017;19(4):475-483. doi:10.1093/neuonc/now240 【17】McDonald MF, Athukuri P, Anand A, et al. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas. Neurosurg Focus. 2022;53(6):E16. doi:10.3171/2022.9.FOCUS22420 【18】Zhang K N , Zhao Z , Chen J ,et al.MET fusions and splicing variants convergently define a subgroup of glioma sensitive to MET inhibitors[J].Holistic Integrative Oncology, 2022, 1.DOI:10.1007/s44178-022-00014-9. 【19】Desai AV, Robinson GW, Gauvain K, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24(10):1776-1789. doi:10.1093/neuonc/noac087 【20】Bouffet E, Larouche V, Campbell BB, et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016;34(19):2206-2211. doi:10.1200/JCO.2016.66.6552 【21】AlHarbi M, Ali Mobark N, AlMubarak L, et al. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. Oncologist. 2018;23(12):1401-1406. doi:10.1634/theoncologist.2018-0163 【22】Cacciotti C, Choi J, Alexandrescu S, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113-122. doi:10.1007/s11060-020-03578-6 【23】Schreck KC, Langat P, Bhave VM, et al. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. NPJ Precis Oncol. 2023;7(1):23. Published 2023 Feb 28. doi:10.1038/s41698-023-00359-y 【24】Torre M, Vasudevaraja V, Serrano J, et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 2020;8(1):107. Published 2020 Jul 14. doi:10.1186/s40478-020-00980-z 【25】Gambella A, Senetta R, Collemi G, et al. NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. Int J Mol Sci. 2020;21(3):753. Published 2020 Jan 23. doi:10.3390/ijms21030753 【26】Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [published correction appears in NPJ Precis Oncol. 2021 Sep 17;5(1):86]. NPJ Precis Oncol. 2021;5(1):69. Published 2021 Jul 20. doi:10.1038/s41698-021-00206-y 【27】Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20(7):1011-1022. doi:10.1016/S1470-2045(19)30277-3 【28】Brown NF, Carter T, Kitchen N, Mulholland P. Dabrafenib and trametinib in BRAFV600E mutated glioma. CNS Oncol. 2017;6(4):291-296. doi:10.2217/cns-2017-0006 【29】Marks AM, Bindra RS, DiLuna ML, et al. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatr Blood Cancer. 2018;65(5):e26969. doi:10.1002/pbc.26969 【30】Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020;38(29):3398-3406. doi:10.1200/JCO.19.03327 【31】Hou Z, Wu H, Luo N, et al. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. Oncologist. 2023;28(5):449-452. doi:10.1093/oncolo/oyac280 【32】Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596-1603. doi:10.1093/annonc/mdp032 【33】Bagchi A, Orr BA, Campagne O, et al. Lorlatinib in a Child with ALK-Fusion-Positive High-Grade Glioma. N Engl J Med. 2021;385(8):761-763. doi:10.1056/NEJMc2101264 【34】Lai M, Li S, Li H, et al. Lorlatinib for ALK-fused, infant-type hemispheric glioma with lung metastasis: a case report. Ann Clin Transl Neurol. 2023;10(5):836-841. doi:10.1002/acn3.51766 【35】Wen PY, Stein A, van den Bent M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53-64. doi:10.1016/S1470-2045(21)00578-7 【36】Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020;38(29):3398-3406. doi:10.1200/JCO.19.03327 【37】Ivosidenib off-label use for IDH mutant gliomas: The MD Anderson Cancer Center real life experience.Meeting Abstract | 2023 ASCO Annual Meeting I.DOI: 10.1200/JCO.2023.41.16_suppl.e14022 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e14022-e14022. 【38】Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023;25(1):4-25. doi:10.1093/neuonc/noac207 【39】https://fore.bio/fore-biotherapeutics-to-present-promising-new-data-from-phase-1-2a-trial-evaluating-plixorafenib-fore8394-in-patients-with-braf-altered-advanced-solid-and-central-nervous-system-tumors-at-asco-2023/ 【40】https://fore.bio/fore-biotherapeutics-announces-oral-presentation-at-sno-2023-reporting-updated-phase-1-2a-results-for-plixorafenib-in-braf-v600-advanced-solid-tumors-including-novel-data-for-patients-with-braf-v600/ 声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

临床3期临床结果临床2期免疫疗法

2024-10-15

·BioSpace

CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer

Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disorder in Older Adults SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has appointed Kathleen Sereda Glaub, MBA, formerly executive chair, as chief executive officer. Dr. Anthony Ford will move to the role of president and chief scientific officer, and continue to lead research and development. Patrick Enright, managing director of Longitude Capital, will become chair of the board. Along with these executive changes, the company announced clinical program updates for its drug candidates that are each designed to restore adrenergic stimulus that declines with age or disease. CuraSen’s most recent development candidate is CuraAX (CST-3056), an alpha-1A adrenoceptor (α 1A -AR) agonist being developed as a treatment for neurogenic orthostatic hypotension (nOH). The company is planning to submit an investigational new drug (IND) application this quarter. A significant orphan indication affecting approximately 120,000-150,000 patients in the U.S., nOH is a dysfunction in the autonomic nervous system common in Parkinson’s disease (PD) and related diseases that causes sudden drops in blood pressure upon standing. This can lead to debilitating dizziness, weakness, cognitive decline and dangerous falls. CuraAX is a selective, CNS-penetrant, α 1A -AR agonist designed to provide cognitive benefit as well as control harmful blood pressure deviations. CuraCN (formerly known as CST-103/CST-107), a beta2 adrenoceptor (β 2 -AR) agonist combination, is targeted for a Phase 2b study in major depressive disorder in adults 65 and older, many of whom also suffer from cognitive decline. These plans are based on the company’s previous Phase 2 clinical study in patients that revealed compelling evidence of anti-depressant efficacy and improvements in cognition tests. CuraXN (formerly known as CST-2032/CST-107), a second β 2 -AR agonist combination, is in development for Alzheimer’s disease (AD) to address both cognitive symptoms and disease progression. All three drug candidates work by restoring adrenergic function that declines with age and, in particular, is lost early in neurodegenerative diseases such as AD & PD. CuraSen’s development candidates have strong potential to improve cognitive function and mood, in addition to addressing specific aspects of disease pathobiology. “We are thrilled to have Ms. Glaub assume the role of chief executive officer as CuraSen seeks to capitalize on the company’s adrenergic platform and clinical data to develop a broad pipeline of drugs for psychiatric and neurodegenerative diseases. These include opportunities for a significant, fast-to-market, orphan opportunity in neurogenic orthostatic hypotension,” said Mr. Enright, board chair. “CuraSen will benefit from the collective and complementary executive experience of both Ms. Glaub and Dr. Ford, both co-founders of the company.” Ms. Glaub brings more than 30 years of experience in biopharmaceutical corporate development, strategy, financing and company-building. She serves on the board of directors of IO Biotech, and previously served on the boards of Codexis, Aligos Pharmaceuticals and Escient Pharmaceuticals. Ms. Glaub was previously chief executive officer of Afferent Pharmaceuticals, which was acquired by Merck in 2016 for $1.25 billion. Under her leadership, the company advanced gefapixant to Phase 3 readiness for the treatment of chronic cough and raised $80 million in additional private funding for Afferent. Previously, she served as president of Plexxikon, and helped develop two FDA-approved drugs, Zelboraf® for metastatic melanoma and Turalio® for tenosynovial giant cell tumor (TGCT). She led Plexxikon’s business and financing strategy, negotiated multimillion-dollar partnerships, and led the sale of the company to Daiichi Sankyo for nearly $1 billion. She previously held positions as senior vice president and chief financial officer of Cell Genesys, treasurer of Genentech, and various finance and treasury roles with Intel Corporation. Ms. Glaub received her BA from the University of California, Berkeley, and her MBA from Northwestern University. “CuraSen’s expertise in adrenergic pharmacology, chemistry and clinical development has led to the discovery of three promising drug candidates focused on some of the most debilitating and common neurodegenerative and psychiatric diseases affecting patients and their families. Our adrenergic target mechanisms are already validated by approved drugs in a range of indications, and we have confirmed the ability to develop CNS-penetrant compounds with a unique approach to safety,” said Glaub. “Given the strong and rapid-onset efficacy signals pointing to an anti-depressant effect in our past studies and our understanding of adrenergic deficits in older adults, we believe there is a unique opportunity to address depression in these patients with CuraCN. With CuraXN, we hope to deliver a transformational treatment for Alzheimer’s disease with our holistic approach to restoring brain functionality and health. Lastly, with CuraAX, we believe we can offer major advantages over current treatments for nOH, including durability of efficacy and cognitive benefit, dosing convenience and improved safety.” About CuraSen Therapeutics CuraSen is focused on the development of new treatments for psychiatric and neurodegenerative diseases, including neurogenic orthostatic hypotension, major depressive disorder and Alzheimer’s disease. CuraSen’s drugs are small molecule, oral tablets designed to activate certain receptor populations in the brain to compensate for decline of the adrenergic system driven by aging and disease. The company has evaluated two β 2 -AR agonist candidates, CuraCN and CuraXN, in multiple Phase 2 clinical studies for effects on memory, attention, executive function and mood, as well as safety and tolerability. CuraSen is planning to submit an IND application by the end of 2024 for its third drug candidate CuraAX, an α 1A -AR agonist, for the treatment of nOH. For more information, please visit . Contacts Susan Kinkead Kinkead Communications susan@kinkeadcomm.com 415-509-3610

临床2期高管变更并购

100 项与维莫非尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09996	维莫非尼	L01XE15	DB08881

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
BRAF突变阳性黑色素瘤	日本	Chugai Pharmaceutical Co., Ltd.	2014-12-26
BRAF V600 突变阳性黑色素瘤	欧盟	Roche Registration GmbH	2012-02-17
BRAF V600 突变阳性黑色素瘤	冰岛	Roche Registration GmbH	2012-02-17
BRAF V600 突变阳性黑色素瘤	挪威	Roche Registration GmbH	2012-02-17
BRAF V600 突变阳性黑色素瘤	列支敦士登	Roche Registration GmbH	2012-02-17
黑色素瘤	美国	Hoffmann-La Roche, Inc.	2011-08-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不可切除的黑色素瘤	临床2期	新西兰	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	临床前	瑞典	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	临床前	美国	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	临床前	澳大利亚	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	药物发现	意大利	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	药物发现	澳大利亚	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	药物发现	瑞典	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	药物发现	意大利	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	药物发现	新西兰	Hoffmann-La Roche, Inc.	2010-01-01
不可切除的黑色素瘤	药物发现	美国	Hoffmann-La Roche, Inc.	2010-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EURETINA2024	N/A	郎格罕细胞组织细胞增生症	-	Vemurafenib	簾願壓鑰積顧簾膚壓餘(膚觸窪壓積鹹壓蓋廠觸) = VKH-like syndrome secondary to dabrafenib 願遞夢窪簾願鹹膚遞蓋 (鹹製築鹹鏇構顧鹽蓋齋 ) 更多	-	2024-09-19
ACTRN12620000861954 (MoST, ESMO2024) 人工标引	临床2期	BRAF突变实体瘤 \| BRAF V600突变阳性非小细胞肺癌一线	64	vemurafenib+cobimetinib (solid tumor)	(鏇齋廠襯鏇鏇積蓋襯齋) = 壓艱製鏇醖餘遞齋網壓衊膚鹽憲觸餘襯餘醖壓 (選淵壓醖選鬱壓醖築鬱 ) 更多	积极	2024-09-14
				vemurafenib+cobimetinib (NSCLC)	(鏇齋廠襯鏇鏇積蓋襯齋) = 鏇鹽膚餘鹽餘積選簾夢衊膚鹽憲觸餘襯餘醖壓 (選淵壓醖選鬱壓醖築鬱 ) 更多
NCT02091141 (MyPathway, CTgov)	临床2期	晚期恶性实体瘤 \| 膀胱癌 \| 胆道癌 \| 唾液腺肿瘤	673	Trastuzumab+Pertuzumab (Trastuzumab Plus Pertuzumab)	觸觸簾遞齋築構觸構醖(願窪鏇鹹鏇襯窪壓餘齋) = 積夢夢醖選齋鑰齋廠齋遞獵壓鹽鏇選積簾觸糧 (淵簾壓膚壓繭網範願鹹, 鑰膚蓋艱構鹽艱構壓獵 ~ 顧獵壓淵衊膚窪顧繭鹹) 更多	-	2024-07-23
				atezolizumab (Atezolizumab)	觸觸簾遞齋築構觸構醖(願窪鏇鹹鏇襯窪壓餘齋) = 鑰夢鏇築遞窪範糧壓衊遞獵壓鹽鏇選積簾觸糧 (淵簾壓膚壓繭網範願鹹, 繭淵餘膚願糧鏇鏇遞蓋 ~ 鹹獵積膚淵簾簾網憲艱) 更多
NCT03101254 (CTgov)	临床1/2期	黑色素瘤	5	LY3022855+cobimetinib+Vemurafenib	壓襯淵鹹選淵襯淵觸鬱(膚艱鑰範鏇積鹽鹽鏇膚) = 觸積餘鹽廠鏇鏇鑰鑰糧製鹽範艱願獵鑰艱餘廠 (鑰築觸構餘遞獵觸醖積, 顧遞鏇蓋醖獵餘選鏇繭 ~ 積鹽網簾廠製鹽遞糧艱) 更多	-	2024-07-17
NCT03781219 (Pubmed) 人工标引	临床1期	BRAF突变实体瘤 BRAF V600	72	Tunlametinib plus Vemurafenib (NSCLC)	(襯齋選顧衊衊餘網廠鑰) = All 72 patients had treatment-related adverse events (TRAEs) 範艱範構顧醖淵餘獵製 (壓網齋築窪憲餘膚鏇憲 ) 更多	积极	2024-06-12
				Tunlametinib 9 mg plus Vemurafenib 720 mg (RP2D)
NCT03625141 (TRICOTEL, ASCO2024) 人工标引	临床2期	BRAF V600 突变阳性黑色素瘤 BRAF V600 mutation	65	Atezolizumab (A) + cobimetinib (C) + vemurafenib (V)	(觸築壓衊鬱餘夢淵積淵) = 齋願襯窪襯窪構繭糧廠夢壓廠齋繭淵鑰顧範窪 (鹹構選願遞遞蓋餘獵廠, 27 ~ 51) 更多	积极	2024-05-24
NCT05263453 (ASCO2024) 人工标引	临床2期	BRAF V600 突变阳性黑色素瘤 BRAF V600-mutant	17	Tunlametinib + vemurafenib	(蓋齋淵醖顧淵構鏇簾鏇) = 網鹹衊艱選構鹹窪鹽鹽觸繭衊糧範觸衊憲窪鬱 (襯夢艱窪繭襯壓鬱餘齋, 44.0 ~ 89.7) 更多	积极	2024-05-24
				Tunlametinib + vemurafenib (pre-treated pts)	(蓋齋淵醖顧淵構鏇簾鏇) = 簾積製鹹築憲窪襯積鑰觸繭衊糧範觸衊憲窪鬱 (襯夢艱窪繭襯壓鬱餘齋, 46.2 ~ 95.0) 更多
HCL-PG04 (EHA2024) 人工标引	临床2期	毛细胞白血病	26	Obinutuzumab +/- VEMURAFENIB	(網範襯積築繭築淵膚餘) = 鏇繭積膚艱衊醖繭鹹簾網糧蓋窪鑰觸願餘網膚 (網網窪觸艱遞選鏇夢願 ) 更多	积极	2024-05-14
NCT03625141 (TRICOTEL, CTgov)	临床2期	肿瘤转移 \| 转移性黑色素瘤 \| BRAF V600 突变阳性黑色素瘤	80	Atezolizumab+Cobimetinib+Vemurafenib (Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib)	蓋憲積鏇齋膚觸願製鬱(鹽鑰鏇餘醖顧鹹製簾齋) = 顧簾壓憲壓艱遞襯鏇鏇窪鏇艱餘淵獵構鬱範衊 (製鏇糧膚繭淵齋簾憲衊, 艱觸鑰廠衊糧襯簾觸網 ~ 窪餘築艱築製窪觸膚餘) 更多	-	2024-02-08
				Atezolizumab+Cobimetinib (Cohort 1- Cobimetinib and Atezolizumab)	鏇選繭淵艱網獵齋築餘(範鏇餘襯淵餘糧夢積餘) = 鑰壓壓鹽鏇窪顧繭觸築鹹鬱構鹹築範簾淵積鑰 (鬱顧積顧餘淵鏇獵獵窪, 膚築鑰壓憲齋壓鏇壓觸 ~ 鬱獵淵繭蓋鏇鑰窪鏇蓋) 更多
HCL-PG03R (ASH2023)	N/A	毛细胞白血病	35	Vemurafenib Plus Rituximab (V+R)	(構簾餘壓簾壓壓鹹築鹽) = 鹹齋積觸選醖顧顧鏇鬱網願蓋觸鹹蓋憲鏇夢壓 (獵淵構築蓋選願襯膚淵 ) 更多	积极	2023-12-10